Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -25.52%. A quarter ago, it was expected that this company would post a loss of $2.40 per share when it actually produced a loss of $1.08, delivering a surprise of 55%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Ginkgo Bioworks, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $43.85 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 2.74%. This compares to year-ago revenues of $34.76 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ginkgo Bioworks shares have added about 6.5% since the beginning of the year versus the S&P 500's gain of 1.7%.
What's Next for Ginkgo Bioworks?
While Ginkgo Bioworks has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ginkgo Bioworks: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.23 on $45.16 million in revenues for the coming quarter and -$5.99 on $202.68 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
CytomX Therapeutics (CTMX), another stock in the same industry, has yet to report results for the quarter ended December 2024.
This biopharmaceutical company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of -2100%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
CytomX Therapeutics' revenues are expected to be $20.13 million, down 24.4% from the year-ago quarter.
Should You Invest in Ginkgo Bioworks Holdings, Inc. (DNA)?
Before you invest in Ginkgo Bioworks Holdings, Inc. (DNA), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ginkgo Bioworks Holdings, Inc. (DNA) : Free Stock Analysis Report
CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates

Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.

Ginkgo Bioworks Holdings To Present At J.P. Morgan Healthcare Conference; Webcast At 1:30 PM ET

(RTTNews) - Ginkgo Bioworks Holdings, Inc. (DNA), Tuesday announced that the company along with Carnegie Mellon University has been awarded a contract of upto $9.4 million to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders.
The project, named Biointegrated Implantable Systems for Cell-based Sensing and Therapy, focuses on implantable bioelectronic devices that utilize engineered cells to produce therapeutic molecules on demand and/or to measure disease biomarkers in realtime.
Under the contract, the company will utilize its capabilities in mammalian cell engineering and induced pluripotent stem cell engineering to create cells that produce and deliver therapeutic molecules and/or monitor the disease status.
Currently, Ginkgo's stock is trading at $9.28, down 1.59 percent on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks, Carnegie Mellon University Secure $9.4 Mln To Build Devices For Disease Treatment

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 55%. A quarter ago, it was expected that this company would post a loss of $3.20 per share when it actually produced a loss of $3.20, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Ginkgo Bioworks, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $89.05 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 102.77%. This compares to year-ago revenues of $55.43 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ginkgo Bioworks shares have lost about 87% since the beginning of the year versus the S&P 500's gain of 25.8%.
What's Next for Ginkgo Bioworks?
While Ginkgo Bioworks has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ginkgo Bioworks: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$2.56 on $42.75 million in revenues for the coming quarter and -$12 on $180.84 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the broader Zacks Medical sector, Patterson Cos. (PDCO), is yet to report results for the quarter ended October 2024.
This medical supplies maker is expected to post quarterly earnings of $0.49 per share in its upcoming report, which represents a year-over-year change of -2%. The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level.
Patterson Cos.'s revenues are expected to be $1.64 billion, down 0.7% from the year-ago quarter.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Ginkgo Bioworks Holdings, Inc. (DNA) : Free Stock Analysis Report
Patterson Companies, Inc. (PDCO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates

(RTTNews) - Ginkgo Bioworks Holdings, Inc. (DNA) revealed Loss for third quarter that decreased from last year
The company's earnings totaled -$56.40 million, or -$1.08 per share. This compares with -$302.89 million, or -$6.21 per share, in last year's third quarter.
The company's revenue for the quarter rose 60.7% to $89.05 million from $55.43 million last year.
Ginkgo Bioworks Holdings, Inc. earnings at a glance (GAAP) :
-Earnings (Q3): -$56.40 Mln. vs. -$302.89 Mln. last year. -EPS (Q3): -$1.08 vs. -$6.21 last year. -Revenue (Q3): $89.05 Mln vs. $55.43 Mln last year.
-Guidance: Full year revenue guidance: $215 - $235 Mln
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks Holdings, Inc. Q3 Loss Declines

(RTTNews) - Ginkgo Bioworks Holdings, Inc. (DNA) will host a conference call at 5:30 PM ET on November 12, 2024, to discuss Q3 24 earnings results.
To access the live webcast, log on to https://investors.ginkgobioworks.com/events/default.aspx
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Ginkgo Bioworks Holdings Q3 24 Earnings Conference Call At 5:30 PM ET

The following companies are expected to report earnings after hours on 11/12/2024. Visit our Earnings Calendar for a full list of expected earnings releases.
Spotify Technology S.A. (SPOT)is reporting for the quarter ending September 30, 2024. The technology services company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.75. This value represents a 386.11% increase compared to the same quarter last year. SPOT missed the consensus earnings per share in the 4th calendar quarter of 2023 by -387.5%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for SPOT is 65.74 vs. an industry ratio of -43.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Suncor Energy Inc. (SU)is reporting for the quarter ending September 30, 2024. The oil company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.88. This value represents a 22.12% decrease compared to the same quarter last year. In the past year SU has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 22.37%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for SU is 11.00 vs. an industry ratio of 9.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Occidental Petroleum Corporation (OXY)is reporting for the quarter ending September 30, 2024. The oil company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.80. This value represents a 32.20% decrease compared to the same quarter last year. In the past year OXY has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2024 Price to Earnings ratio for OXY is 15.44 vs. an industry ratio of 15.90.
Alcon Inc. (ALC)is reporting for the quarter ending September 30, 2024. The medical instruments company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.72. This value represents a 9.09% increase compared to the same quarter last year. ALC missed the consensus earnings per share in the 3rd calendar quarter of 2023 by -1.49%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for ALC is 30.56 vs. an industry ratio of 11.50, implying that they will have a higher earnings growth than their competitors in the same industry.
CAVA Group, Inc. (CAVA)is reporting for the quarter ending September 30, 2024. The restaurant company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.11. This value represents a 83.33% increase compared to the same quarter last year. In the past year CAVA has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 30.77%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for CAVA is 335.91 vs. an industry ratio of 145.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Natera, Inc. (NTRA)is reporting for the quarter ending September 30, 2024. The medical services company's consensus earnings per share forecast from the 6 analysts that follow the stock is $-0.57. This value represents a 40.00% increase compared to the same quarter last year. In the past year NTRA has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 56.52%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for NTRA is -68.35 vs. an industry ratio of 0.70.
Ginkgo Bioworks Holdings, Inc. (DNA)is reporting for the quarter ending September 30, 2024. The biomedical (gene) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-2.40. This value represents a 33.33% increase compared to the same quarter last year. In the past year DNA has met analyst expectations four times Zacks Investment Research reports that the 2024 Price to Earnings ratio for DNA is -0.73 vs. an industry ratio of -3.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Skyworks Solutions, Inc. (SWKS)is reporting for the quarter ending September 30, 2024. The semi-radio frequency company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.25. This value represents a 35.90% decrease compared to the same quarter last year. In the past year SWKS has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 3.13%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for SWKS is 16.89 vs. an industry ratio of -3.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Maplebear Inc. (CART)is reporting for the quarter ending September 30, 2024. The internet company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.22. This value represents a 101.05% increase compared to the same quarter last year. CART missed the consensus earnings per share in the 3rd calendar quarter of 2023 by -20.37%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for CART is 40.80 vs. an industry ratio of 55.90.
Amdocs Limited (DOX)is reporting for the quarter ending September 30, 2024. The information technology services company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.51. This value represents a 20.80% increase compared to the same quarter last year. Zacks Investment Research reports that the 2024 Price to Earnings ratio for DOX is 16.38 vs. an industry ratio of 240.70.
Light & Wonder, Inc. (LNW)is reporting for the quarter ending September 30, 2024. The gaming company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.16. This value represents a 43.21% increase compared to the same quarter last year. LNW missed the consensus earnings per share in the 4th calendar quarter of 2023 by -3.95%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for LNW is 23.48 vs. an industry ratio of 84.60.
MARA Holdings, Inc. (MARA)is reporting for the quarter ending September 30, 2024. The technology services company's consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.38. This value represents a 660.00% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2024 Price to Earnings ratio for MARA is -23.82 vs. an industry ratio of -43.30, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

After-Hours Earnings Report for November 12, 2024 : SPOT, SU, OXY, ALC, CAVA, NTRA, DNA, SWKS, CART, DOX, LNW, MARA

A look at the weighted underlying holdings of the iShares U.S. Tech Breakthrough Multisector ETF (TECB) shows an impressive 1196.6% of holdings on a weighted basis have experienced insider buying within the past six months.
Ginkgo Bioworks Holdings Inc (Symbol: DNA), which makes up 0.01% of the iShares U.S. Tech Breakthrough Multisector ETF (TECB), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $26,988 worth of DNA, making it the #165 largest holding. The table below details the recent insider buying activity observed at DNA:
DNA — last trade: $8.31 — Recent Insider Buys:
Also see:
Top Ten Hedge Funds Holding SBNA
BBAI Videos
Institutional Holders of MHF
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Strong Insider Buying Reported in TECB Holdings

Bioengineering specialist Ginkgo Bioworks Holdings (NYSE: DNA) delivered some badly needed good news for investors on Tuesday. Those folks commensurately rewarded the company by trading up its stock during that day's session, and it closed more than 9% higher in price. That was more than enough to crush the broader market that day, at least in respect to the stagnating S&P 500 index.
Two new products introduced
Ginkgo's news was connected with its efforts in the artificial intelligence (AI) sphere. While that technology isn't as hot as it was for investors several months ago, there is still much interest in its power and potential.
The company unveiled two new products on Tuesday linked to AI. The first is a protein large language model (LLM) it developed with its tech industry partner Alphabet's Google Cloud Consulting unit. According to the biotech, this LLM "will give individual researchers and enterprise companies the ability to develop medicines with insights from Ginkgo's private data."
The company also rolled out its model application programming interface (API; a piece of software that allows different applications to work together). The API, which has been made publicly accessible on Ginkgo's website, allows researchers to work effectively with biological AI models, the company said.
Hope for the future
Ginkgo did not provide any financial details -- costs, pricing, etc. -- of either offering. Regardless, it's clear that investors are enthusiastic about its assertive push into AI and its continuing emphasis on the power of tech to aid in the development of medicines. Shareholders will be hoping that management can turn such efforts into meaningful revenue generators before long.
Should you invest $1,000 in Ginkgo Bioworks right now?
Before you buy stock in Ginkgo Bioworks, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ginkgo Bioworks wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $715,640!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
See the 10 stocks »
*Stock Advisor returns as of September 16, 2024
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today

If a stock is down more than 90% during the past year, you know there's something seriously wrong with the underlying business. Things have gotten so bad for biotech company Ginkgo Bioworks Holdings (NYSE: DNA) that it recently had to do a 1-for-40 reverse stock split to keep its share price up and stay listed on the New York Stock Exchange. It has been in the midst of a stunning free fall as investors appear to have lost patience with the business.
Is the sell-off justifiable, or is this just an overreaction from investors? Let's take a look at why the stock is struggling so much and if there's any reason for investors to consider taking a chance on Ginkgo today.
Ginkgo's losses and cash burn continue to mount
There is a lot of potential in the long run for Ginkgo to help companies develop next-gen, bioengineered products. One of the more exciting opportunities for the business is working to analyze biological data with the help of artificial intelligence (AI) to bring products to market more efficiently. But for all the deals and partnerships that Ginkgo has announced in recent years, including working with big names such as Alphabet, Merck, and Novo Nordisk, the results have simply been underwhelming. Ginkgo has continually posted losses, and its cash burn has been significant.
Ginkgo also isn't proving to be much of a growth investment. Through the first half of the year, the company's sales have totaled $94.2 million, down 42% from the same period last year. The company says it has experienced a significant decline in COVID-19 testing, which provided its top line with a big boost in previous years. But with so many deals and agreements, investors should have arguably expected a lot more growth by now to help offset those declines.
As of the end of June, Ginkgo had $730.4 million in cash and cash equivalents on its books. The problem is that between its operating activities and investing activities, the company used up more than $212 million during the past six months. If that doesn't improve drastically, the company may need to raise cash through debt or a stock offering, which could result in more bearishness and put even greater downward pressure on an already struggling stock.
High short interest suggests there could be wild swings ahead
There are many short-sellers betting against Ginkgo right now. While short interest is lower than it was this time last year, it's still significant at more than 12% of the stock's float.
Whenever there's a high short interest, that's a sign to investors that the stock's movements could be sudden and significant. If Ginkgo does well and proves its doubters wrong, there could be a short squeeze that sends the stock soaring. On the flip side, however, if it does poorly, short-sellers may end up taking on larger short positions, feeling confident that they will be right and that the stock will fall further.
Should you take a chance on Ginkgo's stock?
Ginkgo isn't a stock I would suggest putting in your portfolio today. It's too hard to tell whether the company is indeed on the right path. Its financials are problematic, and at this point, it would be difficult to see a reason why things might be better for the stock in a year or two. I could, in fact, see things getting worse if the company's cash burn remains high and Ginkgo opts to issue shares to raise cash, which would dilute existing shareholders.
This is a high-risk healthcare stock that wouldn't be suitable for the vast majority of investors. Without stronger financials and proof that its operations are sustainable, investors are better off staying away from Ginkgo for the foreseeable future.
Should you invest $1,000 in Ginkgo Bioworks right now?
Before you buy stock in Ginkgo Bioworks, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ginkgo Bioworks wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $661,779!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
See the 10 stocks »
*Stock Advisor returns as of September 3, 2024
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet and Merck. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks Holdings, Inc.

Sign up and unlock all the capabilities of the AI-screener